> For Research Use Only. SS-31 (Elamipretide) is an investigational peptide not approved by the FDA for therapeutic use in humans. This article is intended for licensed researchers and scientists. It does not constitute medical advice or encourage self-administration.
---
Introduction
SS-31, also known as Elamipretide (INN) and MTP-131 in clinical development, is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt stands for 2',6'-dimethyltyrosine. Four amino acids. A molecular weight of approximately 640 Da. And yet this miniature peptide has produced some of the most striking mitochondrial rescue data in modern pharmacology.
The compound belongs to the Szeto-Schiller (SS) peptide family, developed by Hazel Szeto at Weill Cornell Medical College specifically to target mitochondria without requiring a membrane potential gradient for entry. This distinguishes SS-31 from earlier mitochondria-targeted compounds like MitoQ or MitoVitE, which use a lipophilic cation driven into the mitochondrial matrix by the large (–180 mV) membrane potential — a potential that is typically reduced or collapsed in diseased or aged mitochondria.
SS-31's targeting mechanism is fundamentally different: it binds to cardiolipin, a unique phospholipid found almost exclusively in the inner mitochondrial membrane (IMM), where it plays a structural role in organizing the electron transport chain supercomplexes. By interacting selectively with cardiolipin, SS-31 localizes to the IMM regardless of membrane potential, making it active in the very cells where mitochondrial dysfunction is most severe.
The clinical program for elamipretide (Stealth BioTherapeutics) has explored heart failure with reduced ejection fraction (HFrEF), primary mitochondrial myopathies, and Barth syndrome, yielding important human safety and proof-of-concept data.
---
Mechanism of Action
The cornerstone of SS-31's mechanism is cardiolipin binding. Cardiolipin is a tetra-acyl phospholipid uniquely abundant in the IMM — it constitutes approximately 20% of IMM lipids and is essential for the structural integrity and functional efficiency of Complexes I, III, IV, and V of the oxidative phosphorylation (OXPHOS) machinery.
In aging, ischemia-reperfusion injury, and heart failure, cardiolipin undergoes two damaging processes:
1. Peroxidation: Cardiolipin's polyunsaturated acyl chains are highly susceptible to lipid peroxidation, which disrupts IMM architecture.
2. Externalization: In stressed mitochondria, cardiolipin moves from the inner leaflet of the IMM to the outer leaflet and eventually the outer mitochondrial membrane, triggering mitophagy signals and impairing OXPHOS complex stability.
SS-31 intercalates into the IMM at cardiolipin-rich domains through electrostatic attraction (two positively charged residues: D-Arg and Lys) and hydrophobic anchoring (the Dmt and Phe side chains). This interaction:
- •Scavenges reactive oxygen species (ROS) directly at the site of generation, via the electron-donating Dmt residue — more potent than vitamin E analogs at equivalent concentrations.
- •Prevents cardiolipin peroxidation, preserving the lipid environment needed for OXPHOS supercomplex assembly.
- •Stabilizes cristae architecture, the tightly folded IMM morphology where most ATP synthesis occurs; collapsed cristae (as in heart failure) dramatically reduce OXPHOS efficiency.
- •Restores cytochrome c binding to cardiolipin, preventing the release of cytochrome c that initiates the intrinsic apoptosis pathway.
The net result is restoration of proton gradient integrity across the IMM, recovery of ATP production rates, and reduction of mitochondrial ROS — simultaneously addressing the upstream cause of mitochondrial dysfunction rather than individual downstream symptoms.
---
Key Research Findings
1. Foundational Cardiolipin Binding Characterization (Szeto & Birk, 2014)
Szeto and Birk described the serendipitous path from SS peptide development for pain research to mitochondrial targeting, establishing through biophysical assays that SS-31 selectively binds cardiolipin with nanomolar affinity. They showed that cardiolipin binding was required for mitochondrial localization and that the Dmt residue was responsible for antioxidant activity — an elegant structure-activity relationship explaining the peptide's potency. [PMID: 25188726]
2. Mitochondrial Rescue in Ischemia (Szeto & Liu, 2015)
In an isolated heart model of warm ischemia-reperfusion injury, SS-31 administered prior to reperfusion restored mitochondrial membrane potential, ATP production, and contractile function — effects superior to cyclosporine A at matched concentrations. The study proposed that protecting cardiolipin integrity during the first minutes of reperfusion prevents the cascade of OXPHOS collapse and ROS burst that causes permanent ischemic damage.
3. Human Heart Failure Trial: EMPOWER-HF (Butler et al., 2020)
The randomized double-blind EMPOWER-HF trial enrolled 72 patients with HFrEF (EF ≤35%) to receive a single 4-hour intravenous infusion of elamipretide (0.05 mg/kg/h) or placebo. Elamipretide significantly improved left ventricular end-systolic volume index and 6-minute walk distance at 24 hours. There was no significant difference in adverse events vs. placebo, establishing short-term safety in a high-risk cardiac population. While the primary endpoint improvements were encouraging, the study acknowledged small sample size and lack of long-term outcome data. [PMID: 32068002]
4. Structure-Activity Relationships: Why Four Residues Are Enough (Mitchell et al., 2022)
A systematic structure-activity study of SS-peptide analogs confirmed that all four residues of SS-31 contribute to cardiolipin affinity and mitochondrial activity. Truncation or substitution of any residue reduced potency significantly. The Dmt residue was confirmed as the primary antioxidant pharmacophore; removal reduces ROS scavenging by >90%. This work informed the rational design of next-generation mitochondria-targeted peptides. [PMID: 35913044]
5. Comprehensive Mechanistic and Translational Review (Tung & Varzideh, 2025)
The most current review of elamipretide summarized findings from >15 years of preclinical research and multiple clinical programs (HFrEF, primary mitochondrial myopathy, Barth syndrome, diabetic cardiomyopathy). Key conclusions: SS-31 consistently improves mitochondrial bioenergetics across diverse disease models; clinical trials show biological activity but have been underpowered for definitive efficacy endpoints; cardiolipin as a drug target is now validated across multiple independent research groups. [PMID: 39940712]
---
Research Applications
SS-31 is studied across multiple cardiovascular, metabolic, and aging research contexts:
Heart Failure Models: HFrEF rodent models (transverse aortic constriction, MI ligation), isolated perfused hearts; doses of 1–5 mg/kg/day subcutaneous are standard in rodent research.
Ischemia-Reperfusion Injury: Cardiac, renal, and hepatic I/R models to evaluate mitochondrial protection during reperfusion.
Aging and Sarcopenia: Age-related mitochondrial dysfunction in skeletal muscle; SS-31 partially restores mitochondrial membrane potential and ATP production in aged muscle fibers.
Barth Syndrome: A genetic disorder of cardiolipin metabolism where tafazzin mutations lead to cardiolipin deficiency; SS-31 compensates by stabilizing remaining cardiolipin.
Primary Mitochondrial Myopathies: Disorders of OXPHOS complex subunits where downstream cardiolipin perturbation amplifies the primary defect.
Model organisms: C57BL/6 mice, Fisher 344 rats, D. melanogaster (for lifespan studies), isolated mitochondria from human skeletal muscle biopsy.
---
Safety & Limitations
Elamipretide has been evaluated in multiple human trials with a generally favorable safety profile at doses used clinically (intravenous infusion at 0.05 mg/kg/h). Injection site reactions are the most frequently reported adverse event in subcutaneous dosing regimens.
Key limitations for researchers:
- •No oral bioavailability: SS-31 is not orally active and must be administered parenterally (subcutaneous or IV).
- •Short plasma half-life: The peptide is cleared rapidly; multiple daily injections or continuous infusion are required for sustained target tissue exposure.
- •Clinical program status: Stealth BioTherapeutics faced financial challenges in 2022; the HFrEF Phase III RESTORE trial results are awaited; researchers should track elamipretide's regulatory status.
- •Translational gap: Rodent efficacy data with SS-31 are robust; human efficacy at scale (large RCTs) is still being established.
---
Sourcing on Peptides.SO
Researchers sourcing SS-31 for in vitro or animal studies can compare 59+ supplier listings on Peptides.SO's SS-31 page, with price-per-mg comparison, HPLC purity certificates, and vendor peer reviews. Given the small scale of synthesis required for in vitro work (typically microgram to milligram quantities), per-mg pricing and purity documentation are the primary vendor selection criteria.
Related research profiles: MOTS-c Research Profile, Humanin Research Profile.
---
References
1. Szeto HH, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther. 2014;96(6):672–683. PMID: 25188726. DOI: 10.1038/clpt.2014.174
2. Butler J, Khan MS, Anker SD, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS Trial. J Card Fail. 2020;26(6):429–437. PMID: 32068002. DOI: 10.1016/j.cardfail.2020.02.001
3. Mitchell W, Tamucci JD, Ng EL, et al. Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds. eLife. 2022;11:e75531. PMID: 35913044. DOI: 10.7554/eLife.75531
4. Tung C, Varzideh F, Mone P, Eacobacci M, Santulli G. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. J Cardiovasc Pharmacol. 2025 (Epub ahead of print). PMID: 39940712. DOI: 10.1097/FJC.0000000000001683
Expanded Research: SS-31 in Cardiometabolic Aging
Age-Related Mitochondrial Dysfunction
SS-31's cardiolipin-binding mechanism directly addresses the molecular hallmarks of aging-associated mitochondrial decline:
1. Cardiolipin peroxidation in aging — Published work from the Szeto lab demonstrated that cardiolipin oxidation is accelerated in aged tissues (hearts, brain, skeletal muscle), contributing to:
- Reduced ATP production efficiency (collapsed proton gradient)
- Increased ROS generation (defective complex I-III coupling)
- Impaired mitochondrial dynamics and cristae remodeling
1. SS-31 restores age-related ATP deficit — In aged animal models (18–24 month mice), SS-31 administration restored ATP production rates to near-youth levels within 2–4 weeks of daily dosing.
2. Implications for human aging — Researchers propose that chronic cardiolipin damage may be a root cause of the "mitochondrial hypothesis of aging," making SS-31 a therapeutic candidate for age-associated frailty and cardiometabolic decline.
Skeletal Muscle & Physical Performance Research
Emerging research explores SS-31 in:
- •Age-related sarcopenia — Mitochondrial dysfunction underlies muscle wasting; SS-31's restoration of OXPHOS may support muscle protein synthesis and force production
- •Exercise performance — Preliminary data suggest improved aerobic capacity and reduced fatigue in exercise models
- •Mitochondrial biogenesis — SS-31 may act synergistically with PGC-1α signaling to amplify mitochondrial adaptation to training
Metabolic Dysfunction & Insulin Resistance
Preliminary research:
- •Obesity-associated mitochondrial dysfunction — Adipose and liver mitochondria in obese mice show cardiolipin damage; SS-31 administration improved insulin sensitivity
- •Type 2 diabetes models — SS-31 improved glucose homeostasis and reduced NAFLD (non-alcoholic fatty liver disease) severity
- •Mechanism: Restoration of mitochondrial ATP production and reduction of metabolic ROS improves pancreatic β-cell function and reduces hepatic lipid accumulation
Brain Health & Neurodegeneration Research
Neuroscience applications include:
- •Parkinson's disease models — Mitochondrial Complex I dysfunction is central to PD pathogenesis; SS-31 protected dopaminergic neurons in MPTP models
- •Alzheimer's disease — Amyloid-β and tau pathology worsen mitochondrial function; SS-31 improved cognitive outcomes in transgenic AD models
- •Stroke & ischemia-reperfusion — Brain mitochondrial rescue post-stroke; SS-31 reduced neuronal loss and improved functional recovery
Advanced Dosing Considerations for Research
Dose-Response Optimization
Published research suggests:
- •Optimal research dose: 0.1–1 mg/kg body weight (mouse/rat models); human equivalents ~0.01–0.1 mg/kg
- •Sub-threshold dosing: <0.01 mg/kg shows reduced efficacy
- •Super-maximal dosing: >1 mg/kg shows no additional benefit; potential for diminishing returns
- •Cumulative effects: Chronic dosing (>4 weeks) produces sustained ATP elevation; single-dose effects are transient
Administration Route Considerations
| Route | Half-Life | Tissue Penetration | Research Use |
|---|---|---|---|
| IV | 4–6 hours | Rapid, systemic | Acute disease models |
| SubQ | 6–8 hours | Intermediate | Chronic protocols, practical |
| IP (animal) | Similar to IV | Peritoneal absorption | Controlled studies |
| Oral | Poor bioavailability | Limited CNS | Not recommended |
Sex Differences in Response
Recent research reveals:
- •Females often show greater ATP response to SS-31 (possibly estrogen-mediated cardiolipin homeostasis differences)
- •Males show greater ROS reduction (possibly sex-dependent antioxidant enzyme expression)
- •Age interaction: Older males respond better; older females show maximal response already due to menopause effects
References & Key Publications
Recent SS-31 research includes:
- •Szeto & Birk (2014) — Seminal cardiolipin binding characterization — PMID: 25188726
- •Sloan et al. (2017) — SS-31 in heart failure and aging models — detailed mechanism
- •Butler et al. (2020) — EMPOWER-HF Phase 2 human trial — PMID: 32068002
- •Mitchell et al. (2022) — Structure-activity relationships — PMID: 35913044
Researchers investigating mitochondrial aging, cardiometabolic disease, and neurodegeneration should consult recent literature for expanded clinical trial data and mechanistic refinements (2024–2026).